EP2278987A4 - Modulation and repletion/enhancement of the complement system for treatment of trauma - Google Patents
Modulation and repletion/enhancement of the complement system for treatment of traumaInfo
- Publication number
- EP2278987A4 EP2278987A4 EP09724618A EP09724618A EP2278987A4 EP 2278987 A4 EP2278987 A4 EP 2278987A4 EP 09724618 A EP09724618 A EP 09724618A EP 09724618 A EP09724618 A EP 09724618A EP 2278987 A4 EP2278987 A4 EP 2278987A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- repletion
- trauma
- enhancement
- modulation
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4063408P | 2008-03-28 | 2008-03-28 | |
US4063708P | 2008-03-28 | 2008-03-28 | |
US4063508P | 2008-03-28 | 2008-03-28 | |
PCT/US2009/038807 WO2009121065A2 (en) | 2008-03-28 | 2009-03-30 | Modulation and repletion/enhancement of the complement system for treatment of trauma |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2278987A2 EP2278987A2 (en) | 2011-02-02 |
EP2278987A4 true EP2278987A4 (en) | 2012-08-22 |
Family
ID=41114827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09724618A Withdrawn EP2278987A4 (en) | 2008-03-28 | 2009-03-30 | Modulation and repletion/enhancement of the complement system for treatment of trauma |
Country Status (3)
Country | Link |
---|---|
US (1) | US20110190221A1 (en) |
EP (1) | EP2278987A4 (en) |
WO (1) | WO2009121065A2 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
JP2010505946A (en) | 2006-10-10 | 2010-02-25 | アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム | Complement inhibition to improve nerve regeneration |
EP4105224A1 (en) | 2011-05-11 | 2022-12-21 | Apellis Pharmaceuticals, Inc. | Long-acting compstatin analogs and uses thereof |
WO2012162215A1 (en) * | 2011-05-20 | 2012-11-29 | The Trustees Of The University Of Pennsylvania | Promotion of fracture healing using complement inhibitors |
ES2728278T3 (en) | 2011-12-21 | 2019-10-23 | Novartis Ag | Compositions comprising antibodies directed to factor P and C5 |
CA2889170C (en) | 2012-10-25 | 2021-09-07 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
CN108610418B (en) | 2012-11-02 | 2022-11-01 | 美国比奥维拉迪维股份有限公司 | Anti-complement C1s antibodies and uses thereof |
PT3660033T (en) | 2012-11-15 | 2021-07-06 | Apellis Pharmaceuticals Inc | Long-acting compstatin analogs and related compositions and methods |
US10308687B2 (en) | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
US10106579B2 (en) | 2014-06-12 | 2018-10-23 | Ra Pharmaceuticals, Inc. | Modulation of complement activity |
US9937222B2 (en) | 2015-01-28 | 2018-04-10 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
HRP20230093T1 (en) | 2015-04-06 | 2023-03-31 | Bioverativ Usa Inc. | Humanized anti-c1s antibodies and methods of use thereof |
CN117503905A (en) | 2015-10-07 | 2024-02-06 | 阿佩利斯制药有限公司 | dosing regimen |
TWI745320B (en) | 2015-12-16 | 2021-11-11 | 美商Ra製藥公司 | Modulators of complement activity |
JP2019506159A (en) | 2016-01-20 | 2019-03-07 | ヴィトリサ セラピューティクス, インコーポレイテッド | Compositions and methods for inhibiting factor D |
CN110249053A (en) * | 2016-10-17 | 2019-09-17 | 阿佩利斯制药有限公司 | The combination treatment inhibited for C3 |
CN110087668A (en) | 2016-12-07 | 2019-08-02 | Ra制药公司 | The regulator of complement activity |
WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
CA3059304A1 (en) | 2017-04-07 | 2018-10-11 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
WO2019006153A1 (en) * | 2017-06-30 | 2019-01-03 | Anthrobio | Proteolytic cascade enhancement for the treatment of disease |
US20200262879A1 (en) | 2017-09-11 | 2020-08-20 | Insideoutbio, Inc. | Methods and compositions to enhance the immunogenicity of tumors |
GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
US11510939B1 (en) | 2019-04-19 | 2022-11-29 | Apellis Pharmaceuticals, Inc. | RNAs for complement inhibition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006062716A2 (en) * | 2004-11-18 | 2006-06-15 | Yale University | Methods and compositions for treating ocular disorders |
WO2007062249A2 (en) * | 2005-11-28 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Potent compstatin analogs |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981481A (en) * | 1974-12-06 | 1999-11-09 | The Johns Hopkins University | Human C3b/C4b receptor (CR1) |
EP1413587A2 (en) * | 1991-05-03 | 2004-04-28 | Washington University | Modified complement system regulator |
AUPO755097A0 (en) * | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
US6197934B1 (en) * | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
US7084106B1 (en) * | 1999-01-19 | 2006-08-01 | University Of Louisville Research Foundation, Inc. | Application of a viral complement inhibitory protein in the treatment and diagnosis of Alzheimer's Disease |
US7108982B1 (en) * | 1999-02-19 | 2006-09-19 | University Of Iowa Research Foundation | Diagnostics and the therapeutics for macular degeneration |
WO2004026328A1 (en) * | 2002-09-20 | 2004-04-01 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved activity |
CN1787741B (en) * | 2003-05-15 | 2011-08-17 | 唐纳士公司 | Methods and compositions for the prevention and treatment of sepsis |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
JP2008512350A (en) * | 2004-07-01 | 2008-04-24 | イェール ユニバーシティ | Polymeric substances that are targeted and loaded with drugs at high density |
WO2006042252A2 (en) * | 2004-10-08 | 2006-04-20 | Potentia Pharmeceuticals, Inc. | Viral complement control proteins for eye disorders |
US8043609B2 (en) * | 2004-10-08 | 2011-10-25 | Potentia Pharmaceuticals, Inc. | Viral complement control proteins for eye disorders |
US20060257359A1 (en) * | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
JP4438712B2 (en) * | 2005-07-25 | 2010-03-24 | トヨタ自動車株式会社 | Control device for internal combustion engine |
US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
CN101346473A (en) * | 2005-12-22 | 2009-01-14 | 爱尔康研究有限公司 | C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor H |
US20070196367A1 (en) * | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
WO2009015087A2 (en) * | 2007-07-20 | 2009-01-29 | Potentia Pharmaceuticals, Inc. | Compositions and methods for treatment of trauma |
KR20150080007A (en) * | 2007-10-02 | 2015-07-08 | 포텐시아 팔마큐티칼스, 인크. | Sustained delivery of compstatin analogs from gels |
-
2009
- 2009-03-30 WO PCT/US2009/038807 patent/WO2009121065A2/en active Application Filing
- 2009-03-30 EP EP09724618A patent/EP2278987A4/en not_active Withdrawn
- 2009-03-30 US US12/935,251 patent/US20110190221A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006062716A2 (en) * | 2004-11-18 | 2006-06-15 | Yale University | Methods and compositions for treating ocular disorders |
WO2007062249A2 (en) * | 2005-11-28 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Potent compstatin analogs |
Non-Patent Citations (3)
Title |
---|
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 11 June 2007 (2007-06-11), PILLAY NIRVANA S ET AL: "Vaccinia virus complement control protein significantly improves sensorimotor function recovery after severe head trauma.", XP002679788, Database accession no. NLM17467672 * |
MOLLNES T E ET AL: "Strategies of therapeutic complement inhibition", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 43, no. 1-2, 1 January 2006 (2006-01-01), pages 107 - 121, XP027899184, ISSN: 0161-5890, [retrieved on 20060101] * |
PILLAY NIRVANA S ET AL: "Vaccinia virus complement control protein significantly improves sensorimotor function recovery after severe head trauma.", BRAIN RESEARCH 11 JUN 2007 LNKD- PUBMED:17467672, vol. 1153, 11 June 2007 (2007-06-11), pages 158 - 165, ISSN: 0006-8993 * |
Also Published As
Publication number | Publication date |
---|---|
US20110190221A1 (en) | 2011-08-04 |
EP2278987A2 (en) | 2011-02-02 |
WO2009121065A2 (en) | 2009-10-01 |
WO2009121065A3 (en) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2278987A4 (en) | Modulation and repletion/enhancement of the complement system for treatment of trauma | |
HRP20190059T1 (en) | Compositions for the treatment of pain and/or inflammation | |
GB2485291B (en) | Cannabidiol for use in the treatment of generalised and/or partial seizures | |
HK1205005A1 (en) | Bone treatment systems | |
HK1148926A1 (en) | System for cosmetic treatment and imaging | |
EP2361089A4 (en) | Compositions and methods for the treatment of altered -synuclein function | |
IL213070A0 (en) | Methods for the treatment of infections and tumors | |
WO2010075547A9 (en) | Methods and systems for fat reduction and/or cellulite treatment | |
HK1146300A1 (en) | Engineered dendritic cells and uses for the treatment of cancer | |
IL210856A0 (en) | Combination therapy for the treatment of diabetes and related conditions | |
HK1159498A1 (en) | Methods and compositions for the treatment of cancer | |
EP2337535A4 (en) | Systems, devices and methods for the treatment of tinnitus | |
EP2231886A4 (en) | Liquid and solid effluent treatment process | |
HK1162366A1 (en) | Devices and methods for treating and or preventing diseases | |
EP2340027A4 (en) | Methods and compositions for the treatment of cancer | |
EP2313347A4 (en) | Novel systems and methods for wastewater treatment | |
GB2455585B (en) | Capsicum seeds for the treatment of eczema and dermatitis | |
EP2150270A4 (en) | Methods and compositions for the treatment of cancer | |
HK1212218A1 (en) | Organoarsenic compounds and methods for the treatment of cancer | |
SI2225012T1 (en) | Wastewater treatment system and method for the treatment of wastewater | |
EP2437771A4 (en) | Compositions and methods modulating mg29 for the treatment of diabetes | |
GB0808326D0 (en) | Compositions and methods for the treatment of fybromyalgia | |
AU2008902119A0 (en) | Stimulation system for the treatment of tinnitus | |
AU2008905198A0 (en) | Compositions and Methods for the Prevention and Treatment of Cancer | |
AU2008903693A0 (en) | Compositions and methods for the prevention and treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20101022 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120725 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/18 20060101ALI20120713BHEP Ipc: A61K 38/10 20060101AFI20120713BHEP Ipc: A61K 38/08 20060101ALI20120713BHEP Ipc: A61K 39/395 20060101ALI20120713BHEP Ipc: A61K 38/16 20060101ALI20120713BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130226 |